WO2009016410A3 - Chemical compounds 831 - Google Patents

Chemical compounds 831 Download PDF

Info

Publication number
WO2009016410A3
WO2009016410A3 PCT/GB2008/050644 GB2008050644W WO2009016410A3 WO 2009016410 A3 WO2009016410 A3 WO 2009016410A3 GB 2008050644 W GB2008050644 W GB 2008050644W WO 2009016410 A3 WO2009016410 A3 WO 2009016410A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemical compounds
methods
compounds
cancer
salts
Prior art date
Application number
PCT/GB2008/050644
Other languages
French (fr)
Other versions
WO2009016410A2 (en
Inventor
Lynsie Almeida
Brian Aquila
Claudio Edmundo Chuaqui
Huiping Guan
Shan Huang
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Jie Shi
Mei Su
Qibin Su
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Lynsie Almeida
Brian Aquila
Claudio Edmundo Chuaqui
Huiping Guan
Shan Huang
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Jie Shi
Mei Su
Qibin Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009016410(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Lynsie Almeida, Brian Aquila, Claudio Edmundo Chuaqui, Huiping Guan, Shan Huang, Stephanos Ioannidis, Michelle Lamb, Bo Peng, Jie Shi, Mei Su, Qibin Su filed Critical Astrazeneca Ab
Publication of WO2009016410A2 publication Critical patent/WO2009016410A2/en
Publication of WO2009016410A3 publication Critical patent/WO2009016410A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
PCT/GB2008/050644 2007-07-31 2008-07-31 Chemical compounds 831 WO2009016410A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95315807P 2007-07-31 2007-07-31
US60/953,158 2007-07-31

Publications (2)

Publication Number Publication Date
WO2009016410A2 WO2009016410A2 (en) 2009-02-05
WO2009016410A3 true WO2009016410A3 (en) 2009-07-02

Family

ID=40304964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050644 WO2009016410A2 (en) 2007-07-31 2008-07-31 Chemical compounds 831

Country Status (6)

Country Link
AR (1) AR069899A1 (en)
CL (1) CL2008002243A1 (en)
PE (1) PE20090895A1 (en)
TW (1) TW200906818A (en)
UY (1) UY31254A1 (en)
WO (1) WO2009016410A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524505A (en) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 Method and composition for cell Proliferation associated disease
US20120238576A1 (en) * 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
KR20120026612A (en) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 Benzyl substituted triazine derivatives and their therapeutical applications
MX2012000256A (en) 2009-06-29 2012-04-19 Agios Pharmaceuticals Inc Therapeutic compounds and compositions.
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
LT3406251T (en) 2011-05-03 2024-02-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091858A1 (en) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc CISTATIONIN-g-LIASA INHIBITORS (CSE)
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
CN105517996B (en) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 Therapeutical active compound and its application method
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015006591A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
MA39726A (en) 2014-03-14 2017-01-18 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
CN107207435B (en) 2015-01-16 2020-05-19 拜耳作物科学股份公司 Process for preparing 4-cyanopiperidine hydrochloride
HUE063541T2 (en) 2015-06-11 2024-01-28 Agios Pharmaceuticals Inc Methods of using pyruvate kinase activators
CN108472291A (en) 2015-10-15 2018-08-31 阿吉奥斯制药公司 Combination treatment for treating malignant tumour
KR102699521B1 (en) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 Combination therapy for the treatment of malignant tumors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EP3810600A1 (en) * 2018-06-22 2021-04-28 Aduro BioTech, Inc. Triazine compounds and uses thereof
CN109020951B (en) * 2018-08-24 2020-06-02 大连理工大学 Naphthalimide derivative containing trisubstituted cyanuric chloride and synthesis method and application thereof
CN111454214B (en) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 Synthetic method of 2-methoxy-1-pyrimidineethylamine hydrochloride

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022603A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030022885A1 (en) * 2000-12-21 2003-01-30 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20040002496A1 (en) * 2002-03-15 2004-01-01 David Bebbington Compositions useful as inhibitors of protein kinases
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022603A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030022885A1 (en) * 2000-12-21 2003-01-30 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20040002496A1 (en) * 2002-03-15 2004-01-01 David Bebbington Compositions useful as inhibitors of protein kinases
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
TW200906818A (en) 2009-02-16
WO2009016410A2 (en) 2009-02-05
CL2008002243A1 (en) 2009-08-21
AR069899A1 (en) 2010-03-03
UY31254A1 (en) 2009-04-30
PE20090895A1 (en) 2009-08-08

Similar Documents

Publication Publication Date Title
WO2009016410A3 (en) Chemical compounds 831
WO2009013545A3 (en) Chemical compounds
SI2150530T1 (en) Substituted sulfonamide derivatives
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
TW200716606A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2013040227A3 (en) Therapeutic compounds
WO2008131946A3 (en) Substituted amide derivatives
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
TW200800993A (en) Organic compounds
WO2008098143A3 (en) Antimicrobial compounds and methods of use

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776233

Country of ref document: EP

Kind code of ref document: A2